Cargando…

Oncolytic Viruses: Priming Time for Cancer Immunotherapy

New immuno-oncology therapies are improving cancer treatments beyond the former standard of care, as evidenced by the recent and continuing clinical approvals for immunotherapies in a broad range of indications. However, a majority of patients (particularly those with immunologically cold tumors) st...

Descripción completa

Detalles Bibliográficos
Autores principales: Russell, Luke, Peng, Kah Whye, Russell, Stephen J., Diaz, Rosa Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790338/
https://www.ncbi.nlm.nih.gov/pubmed/31321623
http://dx.doi.org/10.1007/s40259-019-00367-0